Instituting Tariffs on Pharmaceutical Imports Without Addressing the Fragile Supply Chain Risks Creating Generic Drug Shortages That Could Endanger the Lives of Cancer Patients
Today, the American Cancer Society Cancer Action Network (ACS CAN) submitted comments in a letter to the U.S. Department of Commerce outlining concerns with instituting tariffs on pharmaceutical imports, especially for older generic sterile injectable (GSI) drugs which have been impacted by drug shortages for more than a decade.